Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
COMM domain-containing protein 1 (COMMD1) is a highly conserved scaffold protein and the founding member of the COMMD family [1, 6]. It plays a critical role in copper homeostasis by interacting with the copper transporters ATP7A and ATP7B to facilitate biliary copper excretion [7, 15]. Beyond copper metabolism, COMMD1 is a key regulator of the NF-kappaB and HIF-1 signaling pathways, typically acting to terminate their activity by promoting the ubiquitination and degradation of their subunits [1, 4, 13]. It is an integral component of the Commander complex, which mediates the endosomal recycling of various transmembrane proteins, including ion channels like ENaC and CFTR [7, 15]. Mutations in COMMD1 are the primary cause of hereditary copper toxicosis in Bedlington Terriers and act as a phenotypic modifier in human Wilson disease [15, 16]. In oncology, COMMD1 often functions as a tumor suppressor, and its downregulation is associated with poor prognosis in several cancers [1, 3]. Experimental therapeutics such as the peptide CIGB-552 target COMMD1 to induce NF-kappaB degradation, offering a novel strategy for treating inflammatory diseases and malignancies [1, 9]. Despite its therapeutic potential, the broad regulatory reach of COMMD1 across multiple essential pathways presents challenges for drug development, as complete loss of the protein is embryonically lethal in animal models [3, 14].
CIGB-552 is a synthetic peptide that interacts with COMMD1, increasing its levels and promoting the ubiquitination and proteasomal degradation of the NF-kappaB subunit RelA (p65), thereby inhibiting NF-kappaB-mediated pro-survival and pro-inflammatory signaling [1, 9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on COMM domain-containing protein 1 (COMMD1) (COMMD1).